Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 209

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 209
---
 ​ | $      | — | ​ | $                  | 10 | ​ | $                  | -10 | ​ | $                   | -1,060 | ​ | $             | -1,060 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4

Liminatus Pharma, Inc. (Succesor to Iris Parent Holding Corp.) Condensed Consolidated Statements of Cash Flows (Unaudited)

| ​                                          
 ​                                          
 ​                                          
 Cash Flows from Operating Activities:      
 ​                                          | ​ 
 ​ 
 ​ | ​                                    
 For the three months ended March 31, 
 2025                                 
 ​                                    
 ​                                    |    ​ 
    ​ | ​ 
 ​ | ​    
 2024 
 ​    
 ​    |    ​ 
    ​ |
|:-------------------------------------------|:--|:-------------------------------------|-----:|:--|:-----|-----:|
| Net loss                                   | ​ | $                                    | -255 | ​ | $    | -247 |
| Changes in current assets and liabilities: | ​ |                                      |      | ​ |      |      |
| Accrued expenses                           | ​ |                                      |  255 | ​ |      |  247 |
| Net cash provided by operating activities  | ​ |                                      |    — | ​ |      |    — |
| ​                                          | ​ | ​                                    |    ​ | ​ | ​    |    ​ |
| Net change in cash                         | ​ |                                      |    — | ​ |      |    — |
| Cash - beginning of the period             | ​ |                                      |    — | ​ |      |    — |
| Cash - end of the period                   | ​ | $                                    |    — | ​ | $    |    — |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-5

<div align='center'>LIMINATUS PHARMA, INC.

(SUCCESSOR TO IRIS PARENT HOLDING CORP.)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

Note 1. Description of Organization and Business Operations

Liminatus Pharma, Inc. (successor to Iris Parent Holding Corp) (“Pharma” or the “Company”) was incorporated in the State of Delaware on November 23, 2022. The purpose of the Company is to facilitate the Business Combination, as further described below.

The